[go: up one dir, main page]

PE20030581A1 - Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo - Google Patents

Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo

Info

Publication number
PE20030581A1
PE20030581A1 PE2002001144A PE2002001144A PE20030581A1 PE 20030581 A1 PE20030581 A1 PE 20030581A1 PE 2002001144 A PE2002001144 A PE 2002001144A PE 2002001144 A PE2002001144 A PE 2002001144A PE 20030581 A1 PE20030581 A1 PE 20030581A1
Authority
PE
Peru
Prior art keywords
compounds
controlled release
polymer compositions
bone growth
mga
Prior art date
Application number
PE2002001144A
Other languages
English (en)
Inventor
Mei Li
Vishwas Madhav Paralkar
Richard Wilker Korsmeyer
Scott Alexander Jeffers
Mingxing Zhou
Richard Lee Dunn
Francis Dumont
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030581A1 publication Critical patent/PE20030581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

QUE COMPRENDE: 1)UN POLIMERO O COPOLIMERO TERMOPLASTICO, BIODEGRADABLE FARMACEUTICAMENTE ACEPTABLE QUE ES INSOLUBLE EN FLUIDO ACUOSO O CORPORAL, SELECCIONADO DE: POLILACTIDOS, POLIGLICOLIDOS Y COPOLIMEROS DE LOS MISMOS, TAL COMO POLI(ACIDO LACTICO-CO-GLICOLICO) (PLGH); 2)UN DISOLVENTE ORGANICO BIOCOMPATIBLE QUE SOLUBILIZA A (1), DISPERSABLE IN SITU EN FLUIDO CORPORAL, MUY SOLUBLE EN AGUA Y CAPAZ DE DISIPARSE DEL SISTEMA DE POLIMERO EN FLUIDO DE TEJIDO CIRCUNDANTE DE MANERA QUE (1) FORMA EL IMPLANTE; 3)APROXIMADAMENTE ENTRE 5 mgA/ml Y 50 mgA/ml DE UN COMPUESTO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, SELECCIONADA DE: ACIDO (3-(((4-TERC-BUTILBENCIL)-(PIRIDIN-3-SULFONIL)AMINO)METIL)FENOXI)ACETICO; ACIDO 7-[(4-BUTILBENCIL)METANOSULFONILAMINO)HEPTANOICO; Y ACIDO 7-{[2-(3,5-DICLOROFENOXI)ETIL]METASULFONILAMINO}HEPTANOICO. DONDE (2) ES N-METIL-2-PIRROLIDONA (NMP) Y EL PORCENTAJE EN PESO DE PLGH A NMP EN SOLUCION SE ENCUENTRA ENTRE 30% Y 60%. SE REFIERE TAMBIEN A UN METODO PARA FORMAR UN IMPLANTE IN SITU EN UN CUERPO VIVO
PE2002001144A 2001-11-30 2002-11-27 Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo PE20030581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33725501P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030581A1 true PE20030581A1 (es) 2003-07-08

Family

ID=23319774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001144A PE20030581A1 (es) 2001-11-30 2002-11-27 Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo

Country Status (34)

Country Link
US (2) US20030104031A1 (es)
EP (1) EP1448166A1 (es)
JP (1) JP4903985B2 (es)
KR (1) KR100629380B1 (es)
CN (1) CN1599598A (es)
AP (1) AP1781A (es)
AR (1) AR037462A1 (es)
AU (2) AU2002347502A1 (es)
BR (1) BR0214610A (es)
CA (1) CA2468703C (es)
DO (1) DOP2002000534A (es)
EA (1) EA011350B1 (es)
EC (1) ECSP045124A (es)
GE (1) GEP20063951B (es)
GT (1) GT200200242A (es)
HR (1) HRP20040486A2 (es)
HU (1) HUP0402135A3 (es)
IL (1) IL161835A0 (es)
IS (1) IS7217A (es)
MA (1) MA27084A1 (es)
MX (1) MXPA04003723A (es)
NO (1) NO20042273L (es)
NZ (1) NZ533115A (es)
OA (1) OA12731A (es)
PA (1) PA8559001A1 (es)
PE (1) PE20030581A1 (es)
PL (1) PL370085A1 (es)
SV (1) SV2004001421A (es)
TN (1) TNSN04096A1 (es)
TW (1) TW200300695A (es)
UA (1) UA76792C2 (es)
WO (1) WO2003045351A1 (es)
YU (1) YU35004A (es)
ZA (1) ZA200402755B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074425B2 (en) * 2002-09-26 2006-07-11 Bonewax, Llc Hemostatic compositions and methods
WO2004071356A2 (en) * 2003-02-10 2004-08-26 Smith & Nephew, Inc. Resorbable devices
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
CN1909911A (zh) * 2003-10-01 2007-02-07 浩鼎生技公司 通过给予氨基糖治疗哺乳动物的疾病状态及其用途
GB0329654D0 (en) 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
US8123787B2 (en) 2004-10-28 2012-02-28 Ogilvie James W Method of treating scoliosis using a biological implant
US8641738B1 (en) 2004-10-28 2014-02-04 James W. Ogilvie Method of treating scoliosis using a biological implant
CA2619571A1 (en) * 2005-08-18 2007-02-22 Smith & Nephew, Plc High strength devices and composites
CN100443065C (zh) * 2006-01-26 2008-12-17 上海交通大学 用于颌面骨缺损修复的复合体系植入体单元
JP2010511751A (ja) 2006-11-30 2010-04-15 スミス アンド ネフュー インコーポレーテッド 繊維強化複合材料
AU2008240418B2 (en) 2007-04-18 2013-08-15 Smith & Nephew Plc Expansion moulding of shape memory polymers
JP5520814B2 (ja) 2007-04-19 2014-06-11 スミス アンド ネフュー インコーポレーテッド マルチモーダル形状記憶ポリマー
AU2008243035B2 (en) 2007-04-19 2013-09-12 Smith & Nephew, Inc. Graft fixation
US8062739B2 (en) * 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
EP2172189A1 (en) * 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
US9642658B2 (en) 2008-10-15 2017-05-09 Orthoclip Llc Device and method for delivery of therapeutic agents via internal implants
US20100130959A1 (en) * 2008-10-15 2010-05-27 Palmetto Biomedical, Inc. Device and method for delivery of therapeutic agents via artificial internal implants
CN102470184B (zh) 2009-08-06 2017-05-31 皇家飞利浦电子股份有限公司 采用放射性种子的肿瘤治疗
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN104189954B (zh) * 2014-09-19 2017-03-29 中国科学院长春应用化学研究所 一种原位固化组织工程支架及其制备方法
RU2571548C1 (ru) * 2014-12-17 2015-12-20 Федеральное государственное бюджетное учреждение науки Институт органической и физической химии им. А.Е. Арбузова Казанского научного центра Российской академии наук Ветеринарное имплантируемое средство пролонгированного действия (варианты)
US10406098B2 (en) 2015-11-16 2019-09-10 Evonik Roehm Gmbh Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
WO2021090146A1 (en) 2019-11-04 2021-05-14 Astrazeneca Ab Combination therapy for treating cancer
IL304103A (en) 2020-12-29 2023-08-01 Sino Medical Sciences Tech Inc drug-eluting stent
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
EP4608390A1 (en) 2022-10-24 2025-09-03 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
EP4649173A1 (en) 2023-01-13 2025-11-19 Akrivia Biomedics Limited Method of profiling diseases
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028124A2 (en) * 1994-04-08 1995-10-26 Atrix Laboratories, Inc. An adjunctive polymer system for use with medical device
WO1996021427A1 (en) 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
CA2275587C (en) * 1996-12-20 2006-10-24 Alza Corporation Injectable depot gel composition and method of preparing the composition
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst

Also Published As

Publication number Publication date
EP1448166A1 (en) 2004-08-25
CA2468703C (en) 2009-12-29
HRP20040486A2 (en) 2004-10-31
PA8559001A1 (es) 2003-11-12
ECSP045124A (es) 2004-07-23
AU2009200125B2 (en) 2012-02-02
YU35004A (sh) 2006-08-17
MA27084A1 (fr) 2004-12-20
UA76792C2 (uk) 2006-09-15
GT200200242A (es) 2003-06-25
WO2003045351A1 (en) 2003-06-05
US20030104031A1 (en) 2003-06-05
NO20042273L (no) 2004-07-14
TW200300695A (en) 2003-06-16
TNSN04096A1 (fr) 2006-06-01
GEP20063951B (en) 2006-10-25
CA2468703A1 (en) 2003-06-05
ZA200402755B (en) 2005-04-08
AP2004003037A0 (en) 2004-06-30
IL161835A0 (en) 2005-11-20
AP1781A (en) 2007-09-27
AU2002347502A1 (en) 2003-06-10
CN1599598A (zh) 2005-03-23
EA200400608A1 (ru) 2004-10-28
HUP0402135A3 (en) 2008-04-28
MXPA04003723A (es) 2005-04-08
JP2005515190A (ja) 2005-05-26
AU2009200125A1 (en) 2009-02-05
HUP0402135A2 (hu) 2005-02-28
AR037462A1 (es) 2004-11-10
EA011350B1 (ru) 2009-02-27
DOP2002000534A (es) 2003-05-31
IS7217A (is) 2004-04-07
JP4903985B2 (ja) 2012-03-28
PL370085A1 (en) 2005-05-16
KR100629380B1 (ko) 2006-09-29
US20090169595A1 (en) 2009-07-02
SV2004001421A (es) 2004-05-07
NZ533115A (en) 2005-12-23
OA12731A (en) 2006-06-28
US8017144B2 (en) 2011-09-13
KR20040062977A (ko) 2004-07-09
BR0214610A (pt) 2004-09-14

Similar Documents

Publication Publication Date Title
PE20030581A1 (es) Composiciones polimeras de liberacion controlada de compuestos que promueven el crecimiento oseo
US20090016990A1 (en) Antimicrobial Compositions
US7087661B1 (en) Safe and effective biofilm inhibitory compounds and health-related uses thereof
CA2513544C (en) An otorhinological delivery device
WO2011089604A3 (en) Material and method for treating internal cavities
CN107261300A (zh) 球囊导管以及用于覆盖医疗球囊的方法
JP2005519904A5 (es)
WO2014186937A1 (zh) 贻贝粘蛋白凝胶的制备方法、贻贝粘蛋白凝胶及其应用
EP1089738A4 (en) ANTIMICROBIAL LOCKS COMPRISING DERIVATIVES OF TAURINAMIDE AND CARBOXYLIC ACIDS AND / OR THEIR SALTS
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
CY1110653T1 (el) Πολυμερικες φαρμακοτεχνικες μορφες απελευθερωσης της λευπρολιδης με βελτιωμενη αποτελεσματικοτητα
KR20140037271A (ko) 유착 방지용 의료용 재료 및 그 제조 방법
WO2007058190A1 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
JP2019030671A (ja) 薬物放出のための化合物及び組成物
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
CY1109669T1 (el) Χρηση υποκατεστημενων παραγωγων της ινδολιζινης 1,2,3 για τη θεραπεια νοσων που σχετιζονται με μια παθολογικη χοριοειδη αγγειογενεση
AR052155A1 (es) Compuestos organicos
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
RU2002117294A (ru) Применение буфера для профилактики кожных инфекций candida albicans
WO2004032854A3 (en) Pharmaceutical compositions for treatment of parkinson's disease
TH63183A (th) สารผสมโพลีเมอริกควบคุมการปลดปล่อยของสารประกอบสนับสนุนการเจริญเติบโตของกระดูก
UY27555A1 (es) Composiciones polímeras de liberación controlada de compuestos que promueven el crecimiento óseo
PE20011105A1 (es) Derivados del acido carboxilico como antagonistas del receptor ip

Legal Events

Date Code Title Description
FC Refusal